GentiBio
Andy Tran is the current director at GentiBio. Prior to this, they were an investment partner at Andreessen Horowitz, where they made seed and Series A investments in early stage ventures at the frontier of biotech and engineering in therapeutics, diagnostics and tools. Andy also served as a board observer at Asimov and Freenome, and as an investor at EQRx and Genesis Therapeutics.
Andy Tran pursued a Master of Business Administration - MBA at Harvard Business School in the field of Bioengineering and Computer Science. Prior to that, they were valedictorian and National AP Scholar at Harvard University in the field of Bioengineering and Computer Science. Andy also attended Michael E. DeBakey High School for Health Professions where they were valedictorian and National AP Scholar.
This person is not in the org chart
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.